Phase 2 Interstitial Lung Disease Trial, Recruiting (NCT05975983)

Phase 2 Interstitial Lung Disease Trial, Recruiting NCT05975983 Sponsor: InSilico Medicine Hong Kong Limited Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05975983 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 40 years of age or older
You have been diagnosed with a lung condition called IPF (Idiopathic Pulmonary Fibrosis), confirmed using recognised international medical guidelines
You are in a stable condition, as confirmed by a general health check including heart tracing (ECG) and blood tests
Your lung function tests during the screening period meet specific requirements: your lungs can hold at least 40% of the normal expected air capacity, your lungs' ability to transfer oxygen into the blood is between 25% and 80% of the normal expected level, and your breathing test shows your airways are not significantly obstructed (confirm with trial site)

Who may not be able to join:

You have had a sudden worsening (flare-up) of your IPF within the 4 months before the study begins
You are unwilling to stop smoking for at least 3 months before the study starts and throughout the entire study
You are currently pregnant or breastfeeding
Your heart tracing test (ECG) shows abnormal results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 18817554306

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05975983

Sponsor: InSilico Medicine Hong Kong Limited

Phase: Phase 2

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: +86 18817554306

More information: https://clinicaltrials.gov/study/NCT05975983

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 40 years of age or older
You have been diagnosed with a lung condition called IPF (Idiopathic Pulmonary Fibrosis), confirmed using recognised international medical guidelines
You are in a stable condition, as confirmed by a general health check including heart tracing (ECG) and blood tests
Your lung function tests during the screening period meet specific requirements: your lungs can hold at least 40% of the normal expected air capacity, your lungs' ability to transfer oxygen into the blood is between 25% and 80% of the normal expected level, and your breathing test shows your airways are not significantly obstructed (confirm with trial site)

Who may not be able to join:

You have had a sudden worsening (flare-up) of your IPF within the 4 months before the study begins
You are unwilling to stop smoking for at least 3 months before the study starts and throughout the entire study
You are currently pregnant or breastfeeding
Your heart tracing test (ECG) shows abnormal results

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

InSilico Medicine Hong Kong Limited

Registry

ClinicalTrials.gov

Start date

8 February 2024

Est. completion

28 February 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of subjects who have at least 1 treatment-emergent adverse event (TEAE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov